Pierre Fabre Brand Guidelines: A Castres Pharmacist’s 1962 Laboratory, Owned by a Foundation

A pharmacist, a château and some fifteen products.

Pierre Fabre began in Castres, a town in the Tarn in south-west France, in 1962. French Wikipedia describes the founder, Pierre Fabre, as a pharmacist and botanist from Castres, and the company calls him a pharmacist “with a passion for botany” who turned his dispensary into an international business while keeping its regional roots.

The local paper tells the story more concretely. In March 1962, La Dépêche du Midi reported in 2016, Pierre Fabre bought the Péraudel estate in the Bisséous district of Castres because he had run out of room in his town-centre pharmacy, where he was making some fifteen products of his own. The paper treats Péraudel as the true birthplace of the Laboratoires: between 1962 and 1970 its château held a reception room, offices and a scientific library, with research laboratories in one wing and manufacturing workshops in the other.

French Wikipedia lists Cyclo 3, a venotonic, as the group’s first medicine, developed the same year, and says the firm bought Laboratoires Inava in 1963. The first Pierre Fabre research centre opened in Castres in 1968, and in 1970 the first subsidiaries abroad were set up in Spain, Portugal, Italy and Germany. The company’s own timeline marks 1982 as its move into medical dermatology and 1989 as its entry into oncology.

Plants, hair care and a spa village.

The consumer side of Pierre Fabre was assembled brand by brand. French Wikipedia says the group bought Klorane in 1965 and calls it the starting point of its dermo-cosmetics business; the company’s timeline lists 1965 as the launch of the brand, and among its “innovation stories” puts a Klorane dry shampoo made with white nettle in 1970. Ducray followed in 1969, and René Furterer, a hair-care name that the company dates to 1957, was bought in 1978, French Wikipedia says.

Another name came from a village. The company says it acquired the spring and spa at Avène in 1975, and launched the Eau Thermale Avène brand in 1990. French and English Wikipedia both record that the Avène laboratories were created in 1989 and that the spa reopened in 1990; the company still runs a hydrotherapy centre there. In 1986 a Japanese joint venture with Shiseido was set up, and in 2000 the dermo-cosmetics division opened an international headquarters at Lavaur, in the Tarn, French Wikipedia adds.

Medicines sit beside the creams. English Wikipedia singles out vinorelbine, sold as Navelbine: an anticancer drug of the vinca alkaloid class that, French Wikipedia says, received its first French marketing authorisation in 1989, with an oral form authorised in 2001. The company has since moved into targeted therapies, which it dates to 2018, and cell therapies, which it dates to 2023, and it opened an innovation centre on the Toulouse Oncopole campus in 2010. English Wikipedia notes that in March 2025 a new head was appointed for its Pierre Fabre Medical Care division.

Today the group lists more than ten brands and franchises, from A-Derma and Naturactive to Pierre Fabre Oral Care, and its staff numbered about 9,650 in 2025, French Wikipedia says, a little over half of them in France.

How mid-sized drug makers present themselves.

Europe’s mid-sized drug makers tend to present themselves through their origins. Many began as a single pharmacist, doctor or industrialist with a laboratory, and their corporate histories still open with a founder, a town and a first product. Family holding companies and foundations often remain in the background as long-term shareholders, and the companies’ own timelines give as much space to new factories and research centres as to the medicines that came out of them.

The visual language that follows is restrained. Corporate sites and annual reports favour photographs of scientists at the bench, production lines seen through glass, and patients in ordinary settings — at home, at work, outdoors — rather than in hospital. Long-serving research campuses, some in use for half a century or more, appear again and again as proof of continuity, alongside newer laboratories in biotech districts abroad.

Identity systems are usually simple: a short word mark or set of initials, a single deep blue or green as the lead colour, and a clean sans for running text. Because prescription medicines cannot be advertised to the general public in the European Union, much of the visible branding lives at medical congresses rather than in shop windows: the dermatology meeting of the EADV, the multiple sclerosis congress of ECTRIMS and the reproductive-medicine meeting of ESHRE are among the places where these companies set up stands, posters and symposia for specialists.

This guide sets out what can be checked about each company — who founded it, who owns it, where it makes and researches its medicines, and how its history is told — and marks plainly what rests only on the company’s own word. The palettes and typefaces shown here are our own interpretations, not official brand assets.

A company owned by its foundation.

What sets Pierre Fabre apart from most drug makers is who owns it. The Fondation Pierre Fabre was recognised as a public-interest foundation in 1999, according to both the company and English Wikipedia. The company says the foundation has been its main shareholder since 2005; French Wikipedia dates the majority holding to a gift by the founder, and records that on 29 August 2008 he announced he had given 65% of the company to the foundation. In 2005, French Wikipedia adds, the capital was also opened to employees.

The company’s governance page, updated in March 2026, puts the foundation’s stake at 86.3% and the employees’ at 9.8%, held through a share scheme called Ruscus that began in France in 2005 and now covers fourteen other countries. The foundation does not run the business: it delegates management to a controlling company, Pierre Fabre Participations, and funds its work on access to medicines and care in low-income countries from the dividends it receives, the company says.

The leadership has changed several times. French Wikipedia records the former GlaxoSmithKline chief Jean-Pierre Garnier as chief executive from 2008, a short-lived successor in 2010, then Jacques Fabre, the founder’s nephew, and later Didier Miraton and Bertrand Parmentier; Éric Ducournau, previously head of the dermo-cosmetics division, has been chief executive since July 2018. In May 2026, the company says, the former Incyte chief Hervé Hoppenot became chair of the supervisory board.

The group has stayed in the Tarn. The company also says it became the main partner of the town’s club, Castres Olympique, in 1988.

For a design guide, Pierre Fabre shows how a pharmacy-born group can hold medicines and dermo-cosmetics under one regional name. Compare Servier, another French drug maker, and Sanofi. For this guide we use a forest green, pale sage and a spring-water blue with a serif, an unofficial interpretation; no product or logo is reproduced.

Keep Pierre Fabre’s identity on hand — save it to a board in the Made Good inspiration library.